Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension.

James L. Pool,John Gennari,Robert E. Goldstein,Mahendr S. Kochar,Andrew Lewin,Morton H. Maxwell,John A. McChesney,Jawahar L. Mehta,David T. Nash,Edward B. Nelson,Shiva Rastogi,Barry A. Rofman,Myron H. Weinberger

Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension.

1987

James L. Pool
John Gennari
Robert E. Goldstein
Mahendr S. Kochar
Andrew Lewin
Morton H. Maxwell
John A. McChesney
Jawahar L. Mehta
David T. Nash
Edward B. Nelson
Shiva Rastogi
Barry A. Rofman
Myron H. Weinberger

Lisinopril (LIS) is a lysine analog of enalaprilat, the active metabolite of enalapril, an angiotensin-converting enzyme inhibitor (ACEI). Unlike enalapril, the precursor of enalaprilat, LIS is not a prodrug but has equal ACEI efficacy and potency and a slightly longer duration of action after oral

Keywords:

Cardiology
Essential hypertension
Lisinopril hydrochlorothiazide
Hydrochlorothiazide
Lisinopril
Diabetes mellitus
Internal medicine
Medicine
Enalapril
Potency
Oral administration
Urology
Placebo
Enalaprilat

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations